ALKS
$27.84-0.17 (-0.59%)
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The ...
Recent News
Is Alkermes (ALKS) Pricing In Its Potential After Recent Share Price Weakness
If you are wondering whether Alkermes at around US$27.64 is pricing in its full potential or leaving some room on the table, you are asking the right question. The stock has seen a 20.4% decline over the past month and a 17.8% decline over the last year, even though the 3 year and 5 year returns sit at 5.3% and 43.2% respectively. Recent attention on Alkermes has centered on its position in the pharmaceuticals and biotech space, and on how markets are reassessing risk and reward for...
New Strong Sell Stocks for March 11th
ALKS, BBSI and CBZ have been added to the Zacks Rank #5 (Strong Sell) List on March 11th, 2026.
Biopharma’s recent string of CEO splits
Leaders at Bavarian Nordic, Sarepta and Alkermes recently announced plans to step down.
Alkermes Pivots Deeper Into Sleep Medicine After Avadel Deal, Details Orexin Phase 3 at TD Cowen
Alkermes (NASDAQ:ALKS) Chairman and CEO Richard Pops told attendees at the 2026 TD Cowen Healthcare Conference that the company entered 2026 with what he described as a strong, cash-generative base business and an expanding focus on sleep medicine, highlighted by its orexin program and the completed
Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change
ALKS beats Q4 earnings and revenue estimates, but shares fall 7%. The company announces a CEO transition plan.